Claudio Anasetti

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Trends in transplantation of hematopoietic stem cells from unrelated donors
    C Anasetti
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Curr Opin Hematol 8:337-41. 2001
  2. ncbi request reprint Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells
    Claudio Anasetti
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA
    Haematologica 87:1-3. 2002
  3. ncbi request reprint Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:552-60. 2004
  4. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
  5. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
  6. pmc Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
    Fabrizio Carnevale-Schianca
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:749-56. 2009
  7. ncbi request reprint Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 10:320-7. 2004
  8. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:3912-8. 2003
  9. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
  10. ncbi request reprint Limits of HLA mismatching in unrelated hematopoietic cell transplantation
    Effie W Petersdorf
    Division of Clinical Research, D4 100 Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 104:2976-80. 2004

Detail Information

Publications65

  1. ncbi request reprint Trends in transplantation of hematopoietic stem cells from unrelated donors
    C Anasetti
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Curr Opin Hematol 8:337-41. 2001
    ..Improved methods for transplantation may provide the opportunity to further decrease treatment-related toxicity and improve survival...
  2. ncbi request reprint Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells
    Claudio Anasetti
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA
    Haematologica 87:1-3. 2002
  3. ncbi request reprint Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:552-60. 2004
    ....
  4. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  5. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
    ..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...
  6. pmc Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
    Fabrizio Carnevale-Schianca
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:749-56. 2009
    ..The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention...
  7. ncbi request reprint Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 10:320-7. 2004
    ..A high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the increased incidence of acute GVHD at our center...
  8. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:3912-8. 2003
    ..Results with unrelated donors were comparable with those with HLA-identical sibling transplants. Thus, allogeneic hematopoietic cell transplantation offers long-term relapse-free survival for patients with myelofibrosis...
  9. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
    ..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality...
  10. ncbi request reprint Limits of HLA mismatching in unrelated hematopoietic cell transplantation
    Effie W Petersdorf
    Division of Clinical Research, D4 100 Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 104:2976-80. 2004
    ..Whenever possible, HLA-C mismatches should be avoided for patients with early stage CML, and HLA-DQB1 mismatches should be avoided for patients with multiple mismatches...
  11. pmc HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation
    Ann Woolfrey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:885-92. 2011
    ..HLA-C antigen-mismatched unrelated PBSC donors were associated with worse outcomes compared with 8/8 HLA-matched donors. The study's limited power due to small sample size precludes conclusions about other mismatches...
  12. ncbi request reprint Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation
    Michael H Albert
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA
    Eur J Immunol 35:2598-607. 2005
    ....
  13. ncbi request reprint Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells
    Xue Zhong Yu
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Immunol 176:3383-90. 2006
    ..These findings underscore that alloantigen affinity and CD4 help control the fate and pathogenicity of alloreactive CD8+ T cells in vivo...
  14. ncbi request reprint Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation
    Uwe Platzbecker
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 43:1409-14. 2002
    ..With a median follow-up of 41 (range 5-116) months after transplant, survival at 3 years is 64%. These data provide evidence that HSCT can be a curative treatment for patients with advanced PV and ET...
  15. ncbi request reprint Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin
    Michael H Albert
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 105:1355-61. 2005
    ..Administration of rapamycin plus agonistic CD28 antibodies offers a promising new therapeutic approach to facilitate tolerance after HCT...
  16. pmc Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia
    Theresa Hahn
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 26:5728-34. 2008
    ..No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved...
  17. pmc CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens
    Xue Zhong Yu
    Human Immunogenetics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Invest 113:1624-30. 2004
    ..This study demonstrates that agonistic Ab's specific for the CD28 costimulatory molecule may be used as novel therapeutic agents to abrogate pathogenic T cell responses by selective depletion of activated T cells...
  18. ncbi request reprint High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation
    Stephanie J Lee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 110:4576-83. 2007
    ..High-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival...
  19. ncbi request reprint HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies
    Michael B Maris
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024
    Blood 102:2021-30. 2003
    ..G-PBMCs conferred higher donor T-cell chimerism, greater durable engraftment, and better progression-free and overall survivals compared with marrow...
  20. ncbi request reprint A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Mailstop D5 290, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 11:465-71. 2005
    ..Survival at 180 days was 32% (95% confidence interval, 18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD...
  21. ncbi request reprint Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
    George B McDonald
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington Schools of Medicine and Pharmacy, Seattle, WA 98109 1024, USA
    Blood 101:2043-8. 2003
    ..Increased exposure to toxic metabolites of cyclophosphamide leads to increased liver toxicity and nonrelapse mortality and lower overall survival after hematopoietic cell transplantation...
  22. ncbi request reprint Lck is required for activation-induced T cell death after TCR ligation with partial agonists
    Xue Zhong Yu
    Human Immunogenetics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Immunol 172:1437-43. 2004
    ..Our data indicate that a selective and distinct TCR signaling pattern is required for AICD by TCR partial agonist ligands...
  23. pmc A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients
    David H Salinger
    Department of Bioengineering, University of Washington, Seattle, Washington 98195 7630, USA
    Clin Cancer Res 15:5280-7. 2009
    ..To this end, we sought to create the first F-ara-A population pharmacokinetic model and subsequently a LSS...
  24. ncbi request reprint Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
    H Joachim Deeg
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:1201-7. 2002
    ..Although there was still considerable nonrelapse morbidity and mortality, the present regimen was used successfully even in patients older than 60 years of age...
  25. ncbi request reprint National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants
    Carolyn Katovich Hurley
    Department of Oncology, Georgetown University, Washington, DC, USA
    Biol Blood Marrow Transplant 9:610-5. 2003
  26. ncbi request reprint Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation?
    Marco Rossi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Hum Immunol 63:1194-200. 2002
    ..In this paper, we review circumstantial evidence that immature plasmacytoid DC might affect immune responses after transplantation of hematopoietic cells from allogeneic donors...
  27. ncbi request reprint CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation
    Xue Zhong Yu
    Human Immunogenetics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Immunol 170:3002-6. 2003
    ..These results indicate that the CD28 signal can down-regulate peripheral T cell responses by increasing apoptosis when TCR ligation exceeds a critical threshold...
  28. pmc Time to consider HPV vaccination after allogeneic stem cell transplantation
    Sara K Tedeschi
    Long Term Follow up Transplant Clinic LTTC, Hematology and Stem Cell Transplantation Section, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5505, USA
    Biol Blood Marrow Transplant 16:1033-6. 2010
    ..It is time to evaluate the immunogenicity and efficacy in preventing HPV-related squamous cell carcinoma in this population...
  29. ncbi request reprint Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone
    Sibel Koc
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:48-51. 2002
    ....
  30. ncbi request reprint "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28
    Philip Tan
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Immunol 169:1119-25. 2002
    ..Humanized 9.3 blocked ligation of CD28-Ig to cells expressing the CD28 receptor CD80. Lastly, the humanized 9.3 showed biological activity as an immunosuppressant by inhibiting a MLR...
  31. ncbi request reprint Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007
    James L M Ferrara
    University of Michigan, Ann Arbor, Michigan, USA
    Biol Blood Marrow Transplant 13:1268-85. 2007
    ..This report summarizes the symposium's discussions and identifies eleven high priority clinical trials that the network plans to pursue over the course of the next several years...
  32. pmc Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects
    Yaming Liang
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Blood 111:954-62. 2008
    ..Our data suggest that strategies to target beta2 integrin have clinical potential to alleviate or prevent GVHD while sparing GVL activity...
  33. ncbi request reprint Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality
    Manuel Jurado
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:161-9. 2002
    ..Future trials should explore the efficacy and tolerability of reduced-intensity conditioning regimens...
  34. ncbi request reprint Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept
    Mohamed A Kharfan-Dabaja
    Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute and University of South Florida, Tampa, FL 33612, USA
    Biol Blood Marrow Transplant 13:373-85. 2007
    ..Treatment of CLL should consider stratification according to modern prognostic markers...
  35. ncbi request reprint Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
    Terry Furlong
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:206-12. 2002
    ..Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin...
  36. pmc Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
    Mary Eapen
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 13:1461-8. 2007
    ..The higher rate of cGVHD after PBSC transplants and, consequently, more frequent late adverse events warrant extended follow up of PBSC recipients...
  37. ncbi request reprint State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants
    Naynesh Kamani
    Biol Blood Marrow Transplant 14:1-6. 2008
  38. pmc To ablate or not to ablate? HSCs in the T cell driver's seat
    Claudio Anasetti
    H Lee Moffitt Comprehensive Cancer Center, Tampa, Florida 33612, USA
    J Clin Invest 117:306-10. 2007
    ..We discuss their results in light of the evolving field and their implications for advancing cell-based immunotherapies for cancer...
  39. pmc Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival
    Daniel Weisdorf
    University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:748-58. 2008
    ..This improved categorization of HLA matching status allows adjustment for donor-recipient HLA compatibility, and can standardize interpretations of prior URD HCT experience...
  40. ncbi request reprint Chemotherapy or allografting for young adults with high-risk ALL?
    Claudio Anasetti
    Blood 111:5755; author reply 5755. 2008
  41. pmc CD28 controls differentiation of regulatory T cells from naive CD4 T cells
    Fei Guo
    Immunology and Blood and Marrow Transplantation Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunol 181:2285-91. 2008
    ..Our study reveals a new aspect of CD28 function in regulating T cell response...
  42. ncbi request reprint A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, USA
    Blood 99:2712-9. 2002
    ..Visilizumab is well tolerated and has activity in advanced GVHD. A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy of visilizumab in GVHD...
  43. ncbi request reprint Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children
    Ann E Woolfrey
    Pediatric Transplantation, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 99:2002-8. 2002
    ..Outcome was particularly favorable in younger patients with early phases of the disease...
  44. ncbi request reprint Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation
    Daniel J Weisdorf
    University of Minnesota Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 99:1971-7. 2002
    ..Improvements in URD and MSD transplantation are still needed, and results of newer, nontransplantation therapies should be evaluated against the established curative potential of URD and MSD marrow transplantation...
  45. ncbi request reprint The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry
    Sherif S Farag
    The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:876-84. 2006
    ..There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing...
  46. ncbi request reprint Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells
    Xue Zhong Yu
    Immunology and Blood and Marrow Transplantation Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunol 176:7394-401. 2006
    ..Our findings indicate that ICOS has paradoxical effects on the regulation of alloreactive CD4(+) and CD8(+) T cells in GVHD...
  47. ncbi request reprint A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    Corey S Cutler
    International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226, USA
    Blood 104:579-85. 2004
    ..For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy...
  48. ncbi request reprint Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome
    Neal Flomenberg
    Department of Medicine and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Blood 104:1923-30. 2004
    ..When clinical circumstances allow, high-resolution class I typing may help optimize donor selection and improve outcome...
  49. ncbi request reprint Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation
    Claudio Anasetti
    Blood and Marrow Transplant Program, H Lee Moffitt Cancer Center and Research Institute, Division of Interdisciplinary Oncology, University of South Florida, Tampa, FL, USA
    Transplantation 77:S79-83. 2004
    ..Graft-versus-host disease (GVHD) is one of the primary challenges to successful HCT. GVHD, its clinical impact and traditional prophylactic therapies, as well as recent advances in GVHD prevention, are discussed...
  50. ncbi request reprint Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation
    Mario Arpinati
    Centro di Ricerca sull Immunologia dei Trapianti, Istituto di Ematologia e Oncologia Medica Seragnoli, Universita di Bologna, Via Massarenti 9, Bologna 40138, Italy
    Transpl Immunol 11:345-56. 2003
    ..The authors will review all the evidence currently available from reports exploring the role of pDC in clinical allogeneic HSCT...
  51. ncbi request reprint Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
    Martin Bornhauser
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany
    Blood 102:820-6. 2003
    ..Based on these encouraging results, further studies of fludarabine and targeted busulfan are warranted in standard-risk patients...
  52. ncbi request reprint Advances in unrelated donor hematopoietic cell transplantation
    Claudio Anasetti
    Haematologica 88:246-9. 2003
  53. ncbi request reprint Selection of unrelated donors for hematopoietic cell transplantation
    Teresa Field
    Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, The University of South Florida, 12901 Magnolia Dr, Tampa, FL 33612, USA
    Curr Hematol Rep 4:270-5. 2005
    ....
  54. ncbi request reprint Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research
    Steven Z Pavletic
    Graft versus Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room CRC 3 3330, Bethesda, MD 20892 1907, USA
    J Clin Oncol 23:5788-94. 2005
    ..To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL)...
  55. ncbi request reprint Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura
    Dietger Niederwieser
    Division of Hematology and Oncology, University of Leipzig, Germany
    Blood 101:1620-9. 2003
    ..HCT from HLA-matched or mismatched unrelated donors can be performed with a reduced intensity conditioning regimen in patients ineligible for conventional HCT...
  56. ncbi request reprint Memory stem cells sustain disease
    Xue Zhong Yu
    Nat Med 11:1282-3. 2005
  57. ncbi request reprint Are matched unrelated donor transplants justified for AML in CR1?
    Claudio Anasetti
    University of South Florida H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 USA
    Best Pract Res Clin Haematol 19:321-8. 2006
    ..AML patients in first remission with unfavorable cytogenetics without a matched family donor should be offered an unrelated donor transplant...
  58. ncbi request reprint Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans
    Myke R Green
    Department of Interdisciplinary Oncology, University of South Florida, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Oncol Pharm Pract 12:179-81. 2006
    ..We describe an allogeneic bone marrow transplant patient, who was found to have vancomycin-resistant Enterococcus durans bacteremia, which subsequently developed resistance to daptomycin...
  59. ncbi request reprint Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients
    Sheri R Jacobs
    University of South Florida and H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Pain Symptom Manage 33:13-23. 2007
    ..However, the FACT-Cog assesses broader aspects of cognitive complaints, thereby providing greater information about the types of cognitive complaints patients are experiencing...
  60. ncbi request reprint ASBMT committee report: white paper on measurement of quality outcomes
    Roy B Jones
    Biol Blood Marrow Transplant 12:594-7. 2006
  61. ncbi request reprint Sympathectomy protects denervated skin from graft-versus-host disease
    Mohamed A Kharfan-Dabaja
    Biol Blood Marrow Transplant 13:369-70. 2007
  62. ncbi request reprint T regulatory cells as an immunotherapy for transplantation
    Michael H Albert
    Dr von Haunersches Kinderspital, University of Munich, Germany
    Expert Opin Biol Ther 6:315-24. 2006
    ..This review will focus on recent advances achieved in the field of transplantation tolerance using naturally occurring Tregs (CD4+CD25+), as well as other Tregs, and will discuss future applications of these cells in immunotherapy...
  63. ncbi request reprint Acquired tolerance to renal allografts in humans
    Claudio Anasetti
    Am J Transplant 3:243-4. 2003
  64. ncbi request reprint The 2006 BBMT Education Supplement
    Claudio Anasetti
    Biol Blood Marrow Transplant 12:1. 2006
  65. ncbi request reprint Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP
    Lia Elena Perez
    Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Immunol 180:1545-55. 2008
    ..In conclusion, the immune cytotoxic effect of Apo2L/TRAIL can be restored at least in part by c-FLIP pathway inhibitors...